An in vitro study was conducted to explore the effect of alcohol on the release characteristics of methylphenidate from the Metadate CD 60 mg capsule dosage form.


Patients were required to have the combined or predominantly hyperactive-impulsive subtype of ADHD; patients with the predominantly inattentive subtype were excluded.

Patients randomized to the Metadate CD group received 20 mg daily for the first week.

2, FDA/E172 Yellow Iron Oxide 20 mg capsules: FD&C Blue No. 2, FDA/E172 Red Iron Oxide 40 mg capsules: FDA/E172 Yellow Iron Oxide 50 mg capsules: FD&C Blue No.

2, FDA/E172 Red Iron Oxide Methylphenidate HCl is a central nervous system (CNS) stimulant.

The plasma levels rose rapidly following the food-induced delay in absorption.

Overall, a high-fat meal increased the C and AUC) of methylphenidate in 26 healthy adults was unaffected by sprinkling the capsule contents on applesauce as compared to the intact capsule.

After oral administration of radiolabeled methylphenidate in humans, methylphenidate was extensively metabolized and approximately 80% of the radioactivity was excreted in the urine in the form of ritalinic acid.

Since renal clearance is not an important route of methylphenidate clearance, renal insufficiency is expected to have little effect on the pharmacokinetics of Metadate CD.

The corresponding values after a 40 mg dose were 16.8 (±5.1) ng/m L, 15.1 (±5.8)* ng/m L and 120 (±39.6) ng•h/m L, respectively.

Tags: , ,